Diabetes medication like Ozempic decrease most cancers dangers: Research

A category of diabetes medicines, which embody the best-selling drug Ozempic, are related to a decreased danger of sure obesity-related cancers, in accordance with a research launched Friday.

Revealed within the journal JAMA, the research in contrast sufferers with Kind 2 diabetes who have been handled with insulin versus sufferers who got a category of drug often known as GLP-1 agonists, like Ozempic, between 2005 and 2018.

The researchers discovered that the sufferers who obtained GLP-1 agonists had a considerably decrease danger of growing 10 out of 13 cancers studied, together with kidney, pancreatic, esophageal, ovarian, liver and colorectal most cancers.

Among the many cancers which noticed no vital change in danger have been thyroid most cancers and breast most cancers in postmenopausal girls.

“Weight problems is well-known to be related to no less than 13 most cancers varieties,” research writer Rong Xu stated in an e-mail to AFP.

“Our research offers proof that GLP-1RAs maintain promise in breaking the hyperlink between weight problems and most cancers,” Xu stated.

Among the many medication studied have been semaglutide—commercially bought as Ozempic—in addition to liraglutide and others. Ozempic was accredited in america in 2017.

GLP-1 agonists have been round for about 20 years, however a brand new technology of those medication, amongst them Ozempic, has been popularized for his or her extra vital weight reduction results.

Xu recommended that the protecting advantages demonstrated within the research could encourage medical doctors to prescribe GLP-1 remedies for diabetes sufferers as a substitute of different medicines like insulin.

© 2024 AFP